Acerus Pharmaceuticals Stock Profit Margin
| ASPCFDelisted Stock | USD 0.22 0.00 0.00% |
Acerus Pharmaceuticals fundamentals help investors to digest information that contributes to Acerus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Acerus OTC Stock. The fundamental analysis module provides a way to measure Acerus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acerus Pharmaceuticals otc stock.
Acerus |
Acerus Pharmaceuticals OTC Stock Profit Margin Analysis
Acerus Pharmaceuticals' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Acerus Pharmaceuticals has a Profit Margin of 0.0%. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The profit margin for all United States stocks is 100.0% lower than that of the firm.
Acerus Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acerus Pharmaceuticals' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Acerus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acerus Pharmaceuticals by comparing valuation metrics of similar companies.Acerus Pharmaceuticals is currently under evaluation in profit margin category among related companies.
Acerus Fundamentals
| Return On Equity | -22.42 | |||
| Return On Asset | -0.54 | |||
| Operating Margin | (8.41) % | |||
| Current Valuation | 49.66 M | |||
| Shares Outstanding | 7.71 M | |||
| Shares Owned By Insiders | 91.41 % | |||
| Price To Book | 20.08 X | |||
| Price To Sales | 2.16 X | |||
| Revenue | (4.13 M) | |||
| Gross Profit | 1 M | |||
| EBITDA | (31.5 M) | |||
| Net Income | (33.82 M) | |||
| Cash And Equivalents | 1.29 M | |||
| Cash Per Share | 0.17 X | |||
| Total Debt | 21.14 M | |||
| Debt To Equity | 2.61 % | |||
| Current Ratio | 0.37 X | |||
| Book Value Per Share | (1.80) X | |||
| Cash Flow From Operations | (23.52 M) | |||
| Earnings Per Share | (3.63) X | |||
| Number Of Employees | 14 | |||
| Beta | 1.35 | |||
| Market Capitalization | 2.09 M | |||
| Total Asset | 9.65 M | |||
| Z Score | -9.9 | |||
| Net Asset | 9.65 M |
About Acerus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acerus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acerus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acerus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Acerus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Acerus Pharmaceuticals' short interest history, or implied volatility extrapolated from Acerus Pharmaceuticals options trading.
Pair Trading with Acerus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acerus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acerus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Acerus OTC Stock
| 0.92 | META | Meta Platforms Earnings Call Today | PairCorr |
| 0.88 | NVDA | NVIDIA Financial Report 22nd of May 2024 | PairCorr |
| 0.86 | AMZN | Amazon Inc Earnings Call Tomorrow | PairCorr |
| 0.84 | TEVA | Teva Pharmaceutical | PairCorr |
| 0.54 | MSFT | Microsoft Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Acerus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acerus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acerus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acerus Pharmaceuticals to buy it.
The correlation of Acerus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acerus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acerus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acerus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Acerus Pharmaceuticals information on this page should be used as a complementary analysis to other Acerus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Acerus OTC Stock
If you are still planning to invest in Acerus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acerus Pharmaceuticals' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |